Cullinan Therapeutics: initiates NDA submission for zipalertinib under RTOR

What happened

• On Oct 1, 2026, Cullinan Therapeutics, Inc. announced the initiation of a new drug application (NDA) submission to the United States Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations under the FDA's Real-Time Oncology Review Program (RTOR). The filing says completion of the NDA submission is expected by year-end 2026.

Key details

• The NDA submission is under the FDA’s RTOR program, which the filing describes as allowing sponsors to submit clinical data in advance to facilitate earlier review of efficacy and safety results.
• The submission is based on data from the Phase 3 REZILIENT3 trial, which the filing says met its primary endpoint, showing a statistically significant and clinically meaningful improvement in median progression-free survival for zipalertinib plus chemotherapy versus chemotherapy alone; results were presented at the International Association for the Study of Lung Cancer’s 2026 World Conference on Lung Cancer during a Presidential Symposium.
• Zipalertinib holds FDA Breakthrough Therapy designation for treatment of patients with locally advanced or metastatic EGFR ex20ins NSCLC who have previously received platinum-based chemotherapy. An NDA seeking accelerated approval for zipalertinib monotherapy is under FDA review with a Prescription Drug User Fee Act target action date of Feb 27, 2027.
• Under the company’s agreement with Taiho, Cullinan is eligible to receive a $30,000,000 payment upon U.S. regulatory approval for previously treated patients and up to a $100,000,000 payment upon U.S. regulatory approval for first-line treatment.

Why it may matter

• Item 7.01 (Regulation FD disclosure) and Item 8.01 (Other events) were reported; the filing furnishes a press release and describes the NDA initiation under RTOR, the REZILIENT3 data supporting the submission, the ongoing monotherapy NDA review with a Feb 27, 2027 PDUFA target date, the Breakthrough Therapy designation, and potential milestone payments from Taiho.
• This filing does not show why the insider traded or why the company acted.